<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625700</url>
  </required_header>
  <id_info>
    <org_study_id>OxyEWS2018</org_study_id>
    <nct_id>NCT03625700</nct_id>
  </id_info>
  <brief_title>Supplementary Oxygen in Surgical and Medical Wards Evaluated by 30-day Mortality</brief_title>
  <acronym>SOSAM</acronym>
  <official_title>Supplementary Oxygen in Surgical and Medical Wards in the Capital Region of Denmark Evaluated by 30-day Mortality, a Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannibal Troensegaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use and effects of supplementary oxygen in surgical and medical
      wards on patients admitted to a hospital in the capital region of Denmark. The population
      will be divided in to three groups according to their oxygenation status. The main outcome
      will be 30-day mortality, with secondary outcomes being Length of stay, 30-day admission to
      ICU, 30-day reoperations, 30-day readmission, and peak values within 30-days of C-reactive
      protein, S-Creatinine, Troponin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30- day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Will be reported as a fraction of positives within the exposure group population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ markers in blood samples</measure>
    <time_frame>30 days</time_frame>
    <description>Highest value of C-reactive protein, Troponin and Creatinine within 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30- day admission to ICU</measure>
    <time_frame>30 days</time_frame>
    <description>Will be reported as a fraction of positives within the exposure group population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30- day readmission</measure>
    <time_frame>30 days</time_frame>
    <description>will be reported as a fraction of positives within the exposure group population.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Oxygen Toxicity</condition>
  <condition>Oxygen Deficiency</condition>
  <arm_group>
    <arm_group_label>Hypoxia</arm_group_label>
    <description>Patients without chronic obstructive pulmonary disease: blood oxygen saturation &lt;94 % irrespective of supplemental oxygen
Patients with chronic obstructive pulmonary disease: blood oxygen saturation &lt;88% irrespective of supplemental oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normoxia</arm_group_label>
    <description>Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.
Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperoxia</arm_group_label>
    <description>Patients without chronic obstructive pulmonary disease: blood oxygen saturation &gt;98% in combination with supplemental oxygen
Patients with chronic obstructive pulmonary disease: blood oxygen saturation &gt;92% in combination with supplemental oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen gas</intervention_name>
    <description>Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.</description>
    <arm_group_label>Hyperoxia</arm_group_label>
    <arm_group_label>Hypoxia</arm_group_label>
    <arm_group_label>Normoxia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is made up of four main population groups, each group having their specific
        vulnerabilities, thus making the main outcome (30-day mortality) more likely to occur than
        in the background population.

        The four groups are:

          1. Patients undergoing laparotomy (open abdominal surgery)

          2. Patients undergoing orthopedic surgery due to hip fracture

          3. Patients admitted to hospital due to chronic obstructive pulmonary disease in
             exacerbation

          4. Patients admitted to hospital with acute mycardial infarction
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission date between 1st of January 2014 to 29th of December 2014 on a hospital in
             the capital region of Denmark

          -  Age ≥18

          -  Unique (first) admission in database for either:

          -  Hip fracture requiring surgery

          -  Chronic obstructive pulmonary disease in exacerbation

          -  Acute mycardial infarction

          -  Open abdominal surgery

        Exclusion Criteria:

          -  No data on saturation within 48 hours after

          -  Admission (Medical patients)

          -  Discharge from the post anaesthesia care unit (Surgical patients)

          -  No data on primary outcome (30-day mortality)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hannibal Troensegaard</last_name>
    <phone>+45 36636239</phone>
    <email>hannibal.troensegaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Meyhoff, P.hd, MD</last_name>
    <email>christian.sahlholt.meyhoff@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bispebjerg og Frederiksberg Hospital</name>
      <address>
        <city>København</city>
        <state>NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannibal Troensegaard</last_name>
      <email>hannibal.troensegaard@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Hannibal Troensegaard</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03625700/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

